Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 3

2(40.0%)

Phase 1

1(20.0%)

5Total

N/A(2)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05054114Not ApplicableCompleted

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

Role: lead

NCT05065905Phase 1Completed

Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis

Role: lead

NCT06118619Unknown

A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis

Role: lead

NCT05359315Unknown

Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis

Role: lead

NCT05386459Completed

Study of the Use of the Drug Ingaron in Patients With COVID-19

Role: lead

NCT05395702Not ApplicableCompleted

Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia

Role: lead

NCT05386446Completed

Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19

Role: lead

NCT05378646Phase 3Completed

Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis

Role: lead

NCT05156541Phase 3Completed

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

Role: lead

All 9 trials loaded